Newsletter | January 7, 2021

01.07.21 -- Unprecedented Growth - And Challenges - In Gene Therapy

Unprecedented Growth — And Challenges — In Gene Therapy
Gene therapy is a rapidly growing area in healthcare but, now that the promise has been shown, we must focus on improving the manufacturing process and reducing costs.
Overcoming Commercialization Challenges For Cell And Gene Therapies

The early promise offered by cell therapies and gene therapies is tempered by the challenges associated with developing, manufacturing, and delivering the drug product to patients. This panel discussion highlights technical and regulatory hurdles associated with development and manufacturing steps, and strategies and solutions to facilitate development through commercialization.

Allogeneic T-Cell Therapies: Efficient Commercial Manufacturing Readiness Using “Manufacturing By Design” Methodology
Contract development and manufacturing organizations need to play a critical role in the scale-up and industrialization of cellular therapies by providing customized tools and processes. The "manufacturing by design" approach for addressing the industrialization of cell therapies allows for optimal production conditions.
Overcoming Scalability Challenges With Autologous Therapies

Autologous immunotherapies have evolved in recent years to bring breakthrough treatments to the market. However, the complexity of the production process often results in extended timelines and high manufacturing costs, limiting the scalability and application across therapeutic indications. This webinar presents a clinical-to-commercial perspective on autologous therapies.